Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Current Treatment Landscape for Second and Subsequent Lines of Therapy in Metastatic Urothelial Carcinoma

Learn how to personalize therapy with immune checkpoint inhibitors and antibody–drug conjugates for patients with urothelial carcinoma previously treated with platinum-based therapy.
person default
Thomas Powles, MBBS, MRCP, MD
Alain Ravaud, MD, PhD
Released: October 15, 2020

This program is divided into several short segments which you can step through using the Video Chapters widget.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for early HCC and advanced BTC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

Video Chapters


Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue